

# Study Group Activities

Currently four Study Groups are active. Non-Committee and Non-Expert Committee members can participate in the Study Groups. A Study Group may host its own seminar with outside speakers at which members present case studies to facilitate free active discussion.

## Environment Accounting Study Group

The Environment Accounting Study Group is set up to investigate the latest trends in environmental accounting, which has been hailed as an effective methodology to coordinate corporate efforts for the environment with their economic activities, to result in a more efficient environmental administration. This group also facilitates multifaceted discussions through the examination of cases and practices by member companies of this group and the Environment & Safety Committee.

Specific activities have included in depth discussions on advanced topics such as "Material Flow Cost Accounting (MFCA)", "Standards for deemed effects calculation", "Cases of monetary conversion of environmental load substances" and "Environmental efficiency assessment indicator". There are also group reading sessions of related academic publications such as "The Green Benefit", the hosting of internal seminars on the risks of soil pollution, organized attendance to the "International Symposium of Environment Accounting", and so on. Actual case studies cover those cases falling under "External environment accounting" whose main purpose is disclosing information in the environmental report and using "Environment management accounting" as a decision-making tool within the firm. We are active in finding methods that may be applied widely in the environmental business operation of pharmaceutical companies.

In FY 2005, we introduced study group member efforts in environmental accounting where we discussed topics such as the "Classification and calculation standards of environmental conservation costs", "Economic effects accompanying

environmental conservation measures, assessment methodology", "Efficient collection method of accounting data and improving precision", etc. Case studies presented by group members included "Decision making methodology in environmentally considerate facility investment" and "Reduction of environmental loads using LCA (Life Cycle Assessment) method". Outside speakers were invited to host the training course, "Integration of MFCA and LIME (Lifecycle Influence Method of Evaluation)".

We will continue to investigate future possibilities of effective utilization in a pharmaceutical company by gathering, collating, and analyzing a wide range of information related to various applicable topics.



## Zero Emission Study Group

It is quite difficult for a pharmaceutical company to reduce the final waste output to zero, as defective products found in the manufacturing process and some liquid wastes are currently quite difficult to recycle. The energy emitted when incinerating waste may be collected and used, thermal recycling, as a way to come close to "Zero Emission". The act of defining "Zero Emission" is very meaningful for a pharmaceutical company. To clarify what thermal recycling is from aspects of environmental conservation, its economic effects, and corporate image perspectives, is important so that attainable waste reduction goals can be set.

This study group comprised of 11 members from nine companies started activities in September to establish the definition of and

methodology for the goals we hope to accomplish. This year our themes are:

- ① Present the current state to each company, redefine Zero Emission
- ② Describe in what ways zero emission is valuable to a pharmaceutical company
- ③ Summarize investigation results, visit to a company that achieved zero emission
- ④ Policy and plan for creating the JPMA Zero Emission Guidelines



## Kyoto Protocol Comprehensive Action Study Group

Since the Kyoto Protocol has come into force from February 2005, specific global warming prevention efforts have been required. In April of the same year, the “Kyoto Protocol Target Completion Plan” was endorsed by the Cabinet, and efforts to reduce emission were further accelerated. Through this Study Group's activities we could achieve a deeper understanding of the greenhouse gas calculation, reporting, and publication system stipulated by the revised Law concerning the Promotion of the Measures to Cope with Global Warming and roles of special goods holders, defined in the revised Law Concerning the Rational Use of Energy (Energy Saving Law). We also investigated and examined specific anti-global warming measures the pharmaceutical company can take, and we made a study visit to a power generation plant with advanced CO<sub>2</sub> emission control in November.

We are now planning to invite outside speakers to speak at a seminar on emission right trading.



Shikoku Electric Power Plant inspection

## Risk Communication / Risk Assessment Study Group

The Risk Communication / Risk Assessment Study Group aims to study the assessment of and response to environmental risks such as soil pollution and the management of chemical substances at the pharmaceutical company. Since FY 2002, we have been meeting every other month and have had a total of 28 sessions as of November 2006.

Our activities related to risk communication include, the presentation of case studies by member companies, seminars by outside speakers, compilation of risk communication Q&A, etc. As for risk assessment, our activities include demonstrations of chemical substance atmospheric dispersion simulation software, etc.

In FY 2006, participating companies were able to achieve a common understanding of the risks through the seminars. For how to respond to the media in an emergency, Mr. Mikio Izawa from Isawa Institute of Risk Management presented “Crises Communication – basic knowledge and tips in responses to media”, and, for corporate risk management in the event of soil pollution,

Mr. Touichiro Maekawa from Kokusai Kogyo Co., Ltd. presented “Risk Control in Soil Pollution”.

We will continue our activities to collect and provide useful information for pharmaceutical companies environmental risk management.



**Mr. MIKIO IZAWA**  
IZAWA Institute of  
Risk Management



**Mr. TOICHIRO MAEKAWA**  
KOKUSAI KOGYO CO.,LTD